INSTALLATION et UTILISATION de ClinTrial Refer IFM

L'application **ClinTrial Refer**, disponible sur smartphone, met à disposition des soignants les informations sur les études en cours de recrutement et les sites d'investigation en France et en Belgique pour les études IFM, et nous espérons bientôt des études industrielles dans le myélome

Si vous avez déjà installé l'application pour accéder aux études du Lysa (que nous remercions pour leurs précieux conseils) il suffit de modifier dans l'onglet My apps, le site préféré et sélectionner IFM pour l'ajouter.

Sinon suivez les étapes suivantes

Recherchez l'application ClinTrial Refer dans l'Apple store ou le Play store selon votre système d'exploitation

Ou téléchargez à partir du site : <u>https://clintrial.org.au/</u>





Et installez

L'Application ClinTrial Refer est commune a de nombreuses organisations principalement en Australie, un sous dossier IFM permet de filtrer les études.



Une fois installée ouvrez l'application avec cette icone :

18:09				••• #antil 51
/	/		$\overline{\ }$	
				Browse
/	ClinT	rial Re	efer	
	Connecting F Clinic	Patients, al Trial S	Doctors &	*
(Ý			
(Ð-			
Get St	arted with Email	/ Mobile	Number	
	Login		Signu	,
	Terms of Serv	ice and Pri	vacy Policy	
		۲	•	

A la première connexion passez par signup, ensuite ce sera login

	fiez-vous avec votre email	
18:00		
\leftarrow		
Welco	ome to	
Clinir	tal Keler	
Email / M	foblie Number	
mo-peti	ilon@chru-lille.fr	
	Continue	
By ta Te	pping "Continue", Lagree to Clinthial Refer's erms & Conditions and Privacy Policy	
0	ra vérifié nar l'envoi d'un lien m	ail
	ra vernie par i envora annen m	
Qui se		an
Qui se	Show Showara Shee Shee Shee Shee -	an
Casharlador - Inst	")agarat ")agaratsaa +)aratu ⊠atan ≜lagarat ()(derusabara	an
Cacharlader - Inst Cacharlader - Inst Cacharlader - Inst Cacharlader - Inst	Tylaporta Tylaportasiana Hardine (Salana Salagoree (Kalena antana	an
Cacharlade - Seat	Theorem Theoremains Theorem Theorem Theorem Theorem Theorem Theorem Theorem Theorem Theorem Theoremains Theorem Theoremains Th	
Curi se	*) Approx *) Approx 2 has 4 houter (in the larger (in the second of the	
Cland Role - Net Clander Role - Net Clander Role - Net Antipaction	*) Approx. *) Approx 2 and *) house ()	
Carlandar - See	*) Approver *) Approver a sus - +) howith () in the case () is how on the case ()	
Carland Selec - Steel Carland Selec - Steel Carland Select - Steel Carland	*) Approver *) Approver a sou : *) however (*) house (*)	

Sur la boite mail, la confirmation est reçue et l'application informe de la vérification

			←
tions de training eCR	Ennov - support 🔿 For Clinicians 🕗 Clinitial Refer	r × + ~	
d=13d96da6-4f13-4137-5	530-d70e1efaad76		Verify Account An email with a link for verification has been sent to email ID:
	ClinTrial Refer		mo-petilion@cnru-lille.rr Confirm your account by checking your email now. Click the link sent to your nominated email to verify your account
	Email id is successfully verified, Please complete your signup process.	-	Email Verified
	Close		Resend Link
		2	

18:14

... #.attl 50

Tell us about yourself

Enter below details to complete your profile.

First Name		P	assv	vord							
		•	•••	•••						Ø	•
Last Name		C.	onfir	m Pas	sword					Ø	,
Select User Profession	•	(C	l woul Trials.	d like to	hear m	ore abo	out Hea	lthy Vo	luntee	ŕ
						Cor	itinue				
dd/mm/yyyy											_
Email Address		1	2	3	4	5	6	7	8	9	0
mo-petillon@chru-lille.fr		а	z	-	Pass	+ word n	ust co	 ontain	: 6	0	р
		q	s	cha	aracter lov	s, at lea /er casi	ast 1 U e and 1	pper c I digit	ase, 1	1	m
FR +33 V Mobile Number		\uparrow		w	х	с	v	b ı	n	ı	$\langle \times \rangle$
Location	0	?123	1	,						•	→I
	v										

Sélectionnez le sous site de l'IFM en application par défaut (et ajoutez le Lysa pour les études Lymphome si utile)

17 ⁶ ad (16)	18:17 tail 🙆) 18:17 dd C
Skip for later	\leftarrow	<i>~</i>
Select Default Apps Select default apps to your account.	Select Primary App Select primary app to your account.	Terms and Conditions & Privacy Policy
	Intergroupe Francophone du	Terms and Conditions:
Haematology WA, Australia	ifm Myélome	Copyright
Healthy Volunteers		This product incorporates software and/or data which is owned by South Eastern Sydney Loca Health District (SELHD) and Sydney Local Health District (SLHD) (in association with the Haematology Clinical research Network, NSW JZ
Intergroupe Francophone du ifm Myélome		Health) © 2013
		Condition of Download – Release and A
LYSA Maridulu Budyari Gumal – SPHERE		Prior to downloading this Clinīrial Refer App (th App), the user agrees, in consideration for, and as a condition to, being able to download the App, that the user releases SESLHD and SLHD (the Licensors) in respect of all liability for loss, damage or injury which may be suffered by the user or any
Melanoma and Skin Cancer Trials		other person arising from or in connection with the App; and further the user agrees to indemnify the Licensors in respect of all liability for loss, damage or injury, which may be suffered by or against any person arising from or in connection with that user's use of the App.
Melanoma Institute Australia Continue	Continue	I Agree to the T&C's

Default App Settings



Vous pouvez choisir d'activer les notifications pour recevoir des mises à jour

Pour la navigation, cliquer sur une étude pour avoir les détails ou rechercher par mots clefs, ou localisation

18:17	fall 300 18:19	Sal 500 18	
Intergroupe	Search Trials in Inter Francophone du My Search for a trial using one or mo	groupe = élome ^{re filters}	\leftarrow \equiv Haematology, Open, relapsed
ifm	Apply Search	Reset	Save Search
	Select health condition	•	Refine Search
Search Trials			Search Results (2)
Available Trials (6)	Select primary sponsor		CONFIRM IFM 2018-07 A Multi-center Phase III Randomized Study
CARRISMM IFM 2017-04 Evaluation of the Impact of the Update Multiple	Enter location	0	Comparing Continuous Versus Fixed Duration Therapy With Daratumumab, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
Myeloma Criteria on the Natural History of Smoldering Myeloma in Order to Establish New Recommendations About Follow-up and Progno Evaluation of Smoldering Myeloma (CARRISMM)	stic Select status	~	IFM 2014-01 Multicenter Open Label Phase 2 Single Arm Study of Ixazomib, Pomalidomide and Dexamethasone
CONFIRM IFM 2018-07 A Multi-center Phase III Randomized Study Comparing Continuous Versus Fixed Duration Therapy With Daratumumab, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma	Enter keywords		in Relapsed or Refractory Multiple Myeloma Characterized With Genomic Abnormalities of Adverse Adverse Prognostic
IFM 2014-01 Multicenter Open Label Phase 2 Single Arm Stud of Ixazomib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Characterized With Canomic Abnormalities of	dy Advanced Filters Search for a trial using advance	bed filters	
		•	

Les informations sont actualisées chaque mois

